Market closedNon-fractional
Avita Therapeutics/RCEL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Avita Therapeutics
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Ticker
RCEL
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Valencia, United States
Employees
207
Website
www.avitamedical.com
RCEL Metrics
BasicAdvanced
$265M
Market cap
-
P/E ratio
-$1.76
EPS
1.42
Beta
-
Dividend rate
Price and volume
Market cap
$265M
Beta
1.42
Financial strength
Current ratio
7.249
Quick ratio
6.347
Long term debt to equity
134.585
Total debt to equity
134.585
Interest coverage (TTM)
-19.99%
Management effectiveness
Return on assets (TTM)
-32.80%
Return on equity (TTM)
-81.39%
Valuation
Price to revenue (TTM)
5.118
Price to book
8.07
Price to tangible book (TTM)
8.21
Price to free cash flow (TTM)
-4.973
Growth
Revenue change (TTM)
35.44%
Earnings per share change (TTM)
66.69%
What the Analysts think about RCEL
Analyst Ratings
Majority rating from 8 analysts.
RCEL Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$11M
-21.28%
Net income
-$19M
165.71%
Profit margin
-167.56%
237.55%
RCEL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.41
-$0.34
-$0.28
-$0.73
-
Expected
-$0.32
-$0.44
-$0.37
-$0.47
-$0.52
Surprise
26.39%
-23.42%
-25.21%
54.27%
-
RCEL News
AllArticlesVideos
AVITA Medical to Announce Second Quarter 2024 Financial Results
GlobeNewsWire·2 weeks ago
AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary
GlobeNewsWire·4 weeks ago
AVITA Medical Achieves Milestone with First Case Using RECELL GO
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Avita Therapeutics stock?
Avita Therapeutics (RCEL) has a market cap of $265M as of July 27, 2024.
What is the P/E ratio for Avita Therapeutics stock?
The price to earnings (P/E) ratio for Avita Therapeutics (RCEL) stock is 0 as of July 27, 2024.
Does Avita Therapeutics stock pay dividends?
No, Avita Therapeutics (RCEL) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Avita Therapeutics dividend payment date?
Avita Therapeutics (RCEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Avita Therapeutics?
Avita Therapeutics (RCEL) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Avita Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.